CS-121 vs Olezarsen

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Familial Chylomicronemia Syndrome

Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline

CS-121

Developed by CorrectSequence Therapeutics

Phase 1 in Familial Chylomicronemia Syndromegene editing (base editing)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07176923 (registry estimate)

No aligned efficacy figure on record for this race.

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Approved in Familial Chylomicronemia Syndromeantisense oligonucleotide
Partial signal

NCT04568434 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 66 patients with a rare disease. Of its two primary comparisons, olezarsen 80 mg lowered triglycerides significantly more than placebo at 6 months (p=0.0009), but olezarsen 50 mg did not (p=0.0775), so the primary result was only partly met.

Next expected readout: June 2027 · NCT05185843 (registry estimate)

Reported efficacy

Percent Change From Baseline in Fasting TG at Month 6: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. (mixed)

Result source: NCT04568434

Results for Familial Chylomicronemia Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

CS-121: no structured comparison results are available for Familial Chylomicronemia Syndrome.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Olezarsen
Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. NCT04568434 · Phase 3 · design grade: moderate · publication or press release

Severe Hypertriglyceridemia

Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline

CS-121

Developed by CorrectSequence Therapeutics

Phase 1 in Severe Hypertriglyceridemiagene editing (base editing)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07657780 (registry estimate)

No aligned efficacy figure on record for this race.

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Approved in Severe Hypertriglyceridemiaantisense oligonucleotide
Reliable signal

NCT05079919 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance.

Next expected readout: March 2027 · NCT05681351 (registry estimate)

Reported efficacy

Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)

Result source: NCT05552326

Results for Severe Hypertriglyceridemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

CS-121: no structured comparison results are available for Severe Hypertriglyceridemia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olezarsen

Fasting TG -57.05% (n=58) vs -7.77% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-60.92% (n=57) vs -7.77% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 150 mg/dL 79.2% (n=53) vs 11.4% (n=35) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
69.8% (n=53) vs 5.7% (n=35) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
84% (n=50) vs 11.4% (n=35) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
82% (n=50) vs 5.7% (n=35) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo C3 -69.63% (n=58) vs -5.47% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-78.72% (n=57) vs -5.47% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Non-HDL-C -22.11% (n=58) vs 3.28% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-19.79% (n=57) vs 3.28% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
HDL-C 48.02% (n=58) vs 8.38% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
48.01% (n=57) vs 8.38% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Remnant Cholesterol -55.98% (n=58) vs -9.46% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-58.17% (n=58) vs -14.83% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-59.59% (n=57) vs -9.46% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-66.9% (n=57) vs -14.83% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo B -11.42% (n=58) vs 6.82% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-11.67% (n=57) vs 6.82% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo A1 17.37% (n=58) vs 2.84% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
16.37% (n=58) vs 0.81% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
14.91% (n=57) vs 2.84% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
15.46% (n=57) vs 0.81% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Total Cholesterol -6.78% (n=58) vs 2.99% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-6.08% (n=58) vs -2.15% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.48% (n=57) vs 2.99% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-10.8% (n=57) vs -2.15% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 500 mg/dL 80% (n=5) vs 75% (n=4) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
100% (n=5) vs 75% (n=4) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Acute Pancreatitis 0% (n=58) vs 0% (n=39) placebo @ 52wk50 mg
event count · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Fasting Triglycerides -62.9% @ 25.98wkolezarsen 50 mg
percent change · % of baseline
No placebo or comparator arm
NCT05079919 · Phase 3 · sponsor-reported, not registry data
show 3 more results
-49.2% @ 25.98wkolezarsen 50 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
-72.2% @ 25.98wkolezarsen 80 mg
NCT05079919 · Phase 3 · sponsor-reported, not registry data
-54.5% @ 25.98wkolezarsen 80 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
Available safety results

Olezarsen

Dropout rate
12.1%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
8.8%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
—80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Serious AEs
10.3%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
14%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mg
injection site erythema 13.8% (placebo 0%)
fatigue 10.3% (placebo 2.6%)
urinary tract infection 10.3% (placebo 15.4%)
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
80 mg
covid-19 7% (placebo 5.1%)
diabetes mellitus 7% (placebo 2.6%)
acute sinusitis 5.3% (placebo 2.6%)
NCT05355402 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS-121's landscape · Olezarsen's landscape